Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US5712298 | ASTRAZENECA | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan, 2020
(4 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5712298 | ASTRAZENECA | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
Jan, 2015
(9 years ago) | |
US8431154 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient |
Feb, 2023
(1 year, 2 months ago) | |
US9468598 | ASTRAZENECA | Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
Feb, 2023
(1 year, 2 months ago) | |
US8618142 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(a month ago) | |
US8536206 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(a month ago) | |
US8604064 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(a month ago) |
Daliresp is owned by Astrazeneca.
Daliresp contains Roflumilast.
Daliresp has a total of 7 drug patents out of which 7 drug patents have expired.
Expired drug patents of Daliresp are:
Daliresp was authorised for market use on 23 January, 2018.
Daliresp is available in tablet;oral dosage forms.
Daliresp can be used as treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations.
Drug patent challenges can be filed against Daliresp from 28 February, 2015.
The generics of Daliresp are possible to be released after 08 March, 2024.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-208) | Aug 31, 2020 |
New Strength(NS) | Jan 23, 2021 |
New Dosing Schedule(D-171) | Jan 23, 2021 |
New Chemical Entity Exclusivity(NCE) | Feb 28, 2016 |
Drugs and Companies using ROFLUMILAST ingredient
NCE-1 date: 28 February, 2015
Market Authorisation Date: 23 January, 2018
Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations
Dosage: TABLET;ORAL